AN2 Therapeutics, Inc. Insider Trading Arrangements
Rule 10b5-1 and other trading arrangements that directors and officers adopted or terminated, as each 10-Q and 10-K tags them (Item 408(a)), newest report first.
- 2026-08-11: .
- 2026-05-11: Individual Eric Easom; Title Chief Executive Officer and a member of our board of directors; Arrangement Rule 10b5-1; Adopted March 11, 2026.
- 2026-05-11: .
- 2025-08-12: Individual Dr. Rob Readnour; Title managing director; Arrangement Rule 10b5-1; Adopted April 17, 2025.
| Report filed | Individual | Title | Arrangement | Adopted | Terminated | Expires or duration | Securities covered |
|---|---|---|---|---|---|---|---|
| 2026-08-11 10-Q | |||||||
| 2026-05-11 10-Q | Eric Easom | Chief Executive Officer and a member of our board of directors | Rule 10b5-1 | March 11, 2026 | March 1, 2027 | 450,000 | |
| 2026-05-11 10-Q | |||||||
| 2025-08-12 10-Q | Dr. Rob Readnour | managing director | Rule 10b5-1 | April 17, 2025 | August 15, 2026 | 582,288 | |
| 2025-08-12 10-Q | Dr. Rob Readnour | managing director | Rule 10b5-1 | April 17, 2025 | August 15, 2026 | 652,573 | |
| 2025-08-12 10-Q | |||||||
| 2025-05-13 10-Q | Gilbert Lynn Marks | member of our board of directors | Rule 10b5-1 | March 31, 2025 | May 15, 2026 | 20,000 | |
| 2025-05-13 10-Q | Eric Easom | Chief Executive Officer and a member of our board of directors | Rule 10b5-1 | March 31, 2025 | December 31, 2025 | 450,000 | |
| 2025-05-13 10-Q | |||||||
| 2024-05-14 10-Q | Joseph Zakrzewski | member of our Board of Directors | Rule 10b5-1 | January 24, 2024 | December 31, 2024 | P342D | 260,000 |
| 2024-05-14 10-Q | |||||||
| 2024-03-29 10-K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |